Northern Star’s 3% Rebound Tests Whether Gold Can Outrun KCGM Execution Risk

May 13, 2026
Northern Star’s 3% Rebound Tests Whether Gold Can Outrun KCGM Execution Risk

Sydney, May 13, 2026, 08:08 (AEST)

  • Northern Star closed Tuesday at A$21.42, up 3.23%, with the move coming after a weak prior session and heavy focus on gold-miner leverage.
  • The rally had two engines: a stronger resources tape during ASX hours and company-specific support from recent cash flow, guidance stabilisation and a A$500 million buyback.
  • The split is still sharp: bulls see a discounted major gold producer with project upside; bears see a stock still hostage to KCGM mill delivery, costs and a shaky rate backdrop.

Northern Star Resources rose 3.23% to A$21.42 on Tuesday, reversing Monday’s 1.94% fall and trading as high as A$21.71. Volume reached about 6.62 million shares, so this was not a quiet bounce. The chart moved because buyers came back to gold exposure after a bruising stretch for the stock, not because a single fresh company announcement landed.

The broader tape helped. By early afternoon, the ASX 200 was still soft, but Market Index noted that resources were “incredibly strong” as gold rebounded during the local session and other commodities also ran. That matters for Northern Star because the stock is one of the cleanest large-cap ASX ways to express a view on gold margins. When the commodity bid returns, NST tends to get looked at fast. Market Index

There is a catch, and it is not small. Later global trading turned less friendly for bullion: spot gold fell 1.2% to US$4,678.49 an ounce as stronger oil fed inflation concerns and revived the idea that rates could stay high. TD Securities’ Bart Melek put the link plainly, saying gold was reacting to the risk that central banks may need to keep policy tighter for longer.

Northern Star’s own numbers explain why buyers were willing to step in anyway. In its March-quarter report, the company sold 381,000 ounces of gold at an all-in sustaining cost, or AISC, of A$2,709 an ounce. AISC is the broad cost measure miners use to capture day-to-day production plus the spending needed to keep mines running. The quarter also produced A$301 million of underlying free cash flow and left the group with A$1.18 billion in cash and bullion.

Management’s tone on the latest call was defensive, but not beaten. Chief executive Stuart Tonkin said the company was “prioritizing cash flow at KCGM” by pulling forward higher-grade Golden Pike material while the old mill remains constrained. That phrase matters. Investors are not paying for generic ounces here; they are paying for cleaner execution at Kalgoorlie after a messy start to 2026. Investing

The buyback is part of the same repair trade. Northern Star has approval to buy back up to A$500 million of shares over 12 months from around April 23, subject to market conditions. Tonkin said the program reflected the “compelling value” seen in the share price, but the company also made clear it may not buy the full amount. A buyback can help reduce the share count and support earnings per share, but it cannot fix a mill.

That mill remains the centre of the stock. Northern Star has cut FY26 group production guidance to above 1.5 million ounces, while KCGM sales are now expected at 450,000 to 480,000 ounces, down from the earlier 520,000 to 550,000 range. The company kept AISC guidance at A$2,600 to A$2,800 an ounce despite lower sales and higher expected diesel costs, and said the KCGM mill expansion remains on track for commissioning in early FY27.

Peers show this was a sector bid, not just a Northern Star story. Evolution Mining rose 2.78% to A$13.32, Newmont’s ASX line gained 4.37% to A$165.79, and Bellevue Gold climbed 4.98% to A$1.685. The market was buying Australian gold leverage broadly, though Northern Star’s move carried extra baggage because its March downgrade left more room for a relief rally.

The bullish case is straightforward: Northern Star has scale, cash generation, a live buyback and two major levers in KCGM and Hemi. Morningstar Australia’s Tyger Fitzpatrick cited global mining analyst Jon Mills’ view that Northern Star is the cheapest relative name among covered ASX gold miners, with Kalgoorlie expected to drive a large share of future output and Hemi potentially adding 500,000 ounces by 2030.

The bearish answer is just as direct. Morningstar’s same work says ASX gold miners still trade well above fair value on long-run gold assumptions, and Northern Star remains “materially overvalued” if spot gold falls back toward midcycle levels. Add KCGM throughput risk, fuel cost pressure and a guidance history investors have not forgotten, and the stock still has a thin margin for error. Morningstar

Rate expectations also cut against a clean gold bull story. Kalshi markets showed roughly 96% odds that the Fed maintains rates at the June meeting and about 61% odds of exactly zero U.S. rate cuts in 2026; Polymarket showed a similar picture, with “No change” near 98% for June and zero 2026 cuts around 63%. Higher rates raise the opportunity cost of holding gold, which pays no income, so this is the macro pressure point sitting behind every gold-miner rally now. Kalshi

So Tuesday’s move was real, but not clean. Northern Star’s chart improved because investors bought resource strength, recent cash flow and the buyback signal after a hard reset in expectations. For the rally to hold, gold needs to avoid a rate-driven reversal, and Northern Star needs to show that KCGM is moving from explanation to delivery.

Stock Market Today

  • Cogstate: A Leading ASX Healthcare Stock in Alzheimer's Clinical Trials
    May 12, 2026, 5:54 PM EDT. Alzheimer's is now Australia's top cause of death, creating urgent demand for innovative treatments. Cogstate Ltd (ASX: CGS), an Australian firm, provides cognitive testing services critical to clinical trials of new Alzheimer's drugs. With the FDA approving several treatments through 2024-25, Cogstate plays a key role in accelerating drug development by offering data that influence trial speed and success. The company's revenue stems mainly from ongoing trials, and it operates globally amid competitors. Analysts highlight Cogstate's strong data-driven approach, or "data flywheel," as a competitive moat. While pharmaceutical buyouts are possible, Cogstate remains dependent on drug development funding. Investors watch trial pipelines and annual reports closely to assess risk and future growth, including prospects beyond Alzheimer's into other central nervous system disorders.